Tolmetin
File:Tolmetin Structural Formulae.png | |
Systematic (IUPAC) name | |
---|---|
[1-methyl-5-(4-methylbenzoyl)-1H-pyrrol-2-yl]acetic acid | |
Clinical data | |
Routes of administration | oral |
Pharmacokinetic data | |
Biological half-life | 1-2 hours, next phase up to 5 hours |
Identifiers | |
CAS Number | 26171-23-3 |
ATC code | M01AB03 (WHO) M02AA21 |
PubChem | CID 5509 |
DrugBank | APRD01268 |
Chemical data | |
Formula | C15H15NO3 |
Molar mass | 257.285 g/mol[[Script error: No such module "String".]] |
Script error: No such module "collapsible list". | |
(verify) |
Tolmetin (pronounced /ˈtɒlmətɨn/) is a non-steroidal anti-inflammatory drug of the arylalkanoic acids. It is used primarily to reduce hormones that cause pain, swelling, tenderness, and stiffness in conditions such as osteoarthritis and rheumatoid arthritis, including juvenile rheumatoid arthritis. In the United States it is marketed as Tolectin and comes as a tablet or capsule.
Tolmetin can increase the risk of heart or circulatory conditions such as heart attacks and strokes. It should not be taken shortly before or after coronary artery bypass surgery.[1] Tolmetin can also increase the risk of gastrointestinal conditions such as perforation or bleeding, which is fatal. Antacids can be taken with tolmetin to relieve stomachaches that often occur.[1] Overdose can result in drowsiness, nausea, epigastric pain, and vomiting.
When tested in rats tolmetin prevented experimentally stimulated polyarthritis and reduced inflammation. In patients with rheumatoid arthritis or osteoarthritis tolmetin restrained disease activity as efficiently as aspirin and indometacin, although the occurrence of mild gastrointestinal adverse effects and tinnitus was lower in patients treated with tolmetin than it was with aspirin-treated patients and the occurrence of adverse effects of the central nervous system was lower with tolmetin than it was with indometacin.[2]
Although the mechanism of action of tolmetin is unknown, research involving humans and animals has shown that tolmetin does not achieve anti-inflammatory response by stimulation of the adrenal or pituitary gland, but it has shown tolmetin restrains prostaglandin synthetase in vitro and reduces plasma of prostaglandin E, possibly causing the anti-inflammatory response. 500px
http://dx.doi.org/10.1021/jm00289a026
References
- ↑ 1.0 1.1 "Tolmetin". MedlinePlus. Retrieved 2007-07-02.
- ↑ "Tolmetin". DrugBank. Retrieved 2007-07-02.
45px | This drug article relating to the musculoskeletal system is a stub. You can help ssf by expanding it. |
- Pages with script errors
- Pages with broken file links
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Drugboxes which contain changes to watched fields
- 2Fix
- Non-steroidal anti-inflammatory drugs
- Pyrroles
- Aromatic ketones
- Musculoskeletal system drug stubs